[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,989,052
  • Shares Outstanding, K 105,576
  • Annual Sales, $ 2,198 M
  • Annual Income, $ -713,410 K
  • EBIT $ -38 M
  • EBITDA $ 1 M
  • 60-Month Beta 0.26
  • Price/Sales 0.92
  • Price/Cash Flow N/A
  • Price/Book 1.34

Options Overview Details

View History
  • Implied Volatility 59.08% (+2.47%)
  • Historical Volatility 51.05%
  • IV Percentile 2%
  • IV Rank 1.80%
  • IV High 193.83% on 07/24/25
  • IV Low 56.62% on 05/13/26
  • Expected Move (DTE 1) 0.89 (4.75%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 787
  • Volume Avg (30-Day) 2,658
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 115,719
  • Open Int (30-Day) 114,341
  • Expected Range 17.88 to 19.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.76
  • Number of Estimates 5
  • High Estimate $2.31
  • Low Estimate $-0.14
  • Prior Year $1.70
  • Growth Rate Est. (year over year) -55.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.38 +3.97%
on 04/23/26
23.49 -18.65%
on 05/06/26
-3.04 (-13.72%)
since 04/14/26
3-Month
15.52 +23.09%
on 03/06/26
23.85 -19.87%
on 03/25/26
+1.32 (+7.42%)
since 02/13/26
52-Week
10.41 +83.49%
on 07/24/25
44.14 -56.71%
on 05/21/25
-16.63 (-46.53%)
since 05/14/25

Most Recent Stories

More News
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets...

SRPT : 19.11 (+1.43%)
Sarepta Therapeutics: Q1 Earnings Snapshot

Sarepta Therapeutics: Q1 Earnings Snapshot

SRPT : 19.11 (+1.43%)
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues ...

SRPT : 19.11 (+1.43%)
Sarepta's Gene Therapy Deaths Still Casting Shadow Over Elevidys Revenue Trajectory

Barchart Research What to Expect from SRPT Earnings SRPT Generated May 5, 2026 Current Price $21.79 EPS Estimate $$0.39 Consensus Rating Hold Average Move 10.74% Sarepta's Gene Therapy Deaths Still Casting...

SRPT : 19.11 (+1.43%)
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday,...

SRPT : 19.11 (+1.43%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee...

SRPT : 19.11 (+1.43%)
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

In early clinical results, Sarepta’s αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 ...

SRPT : 19.11 (+1.43%)
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

In early clinical results, Sarepta’s αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 ...

SRPT : 19.11 (+1.43%)
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast...

SRPT : 19.11 (+1.43%)
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast...

SRPT : 19.11 (+1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 19.91
2nd Resistance Point 19.62
1st Resistance Point 19.23
Last Price 19.11
1st Support Level 18.55
2nd Support Level 18.26
3rd Support Level 17.87

See More

52-Week High 44.14
Fibonacci 61.8% 31.26
Fibonacci 50% 27.28
Fibonacci 38.2% 23.30
Last Price 19.11
52-Week Low 10.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.